![](/wp-content/uploads/2024/03/Screenshot-2024-03-28-at-4.36.49%E2%80%AFPM.png)
$599
FDA Approves Akebia’s Vadadustat; Inventiva and NeuroBo Q4 ’23 Earnings; Supersapiens to Relaunch in US; Sagimet MASH Development Updates
A series of cardiometabolic-related news items have been observed from Akebia Therapeutics, Inventiva, Supersapiens, Sagimet Biosciences, and NeuroBo Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.